These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16210663)

  • 1. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
    Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
    Lee JC; Lee KM; Kim DW; Heo DS
    J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
    J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
    Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
    J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
    Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
    Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
    Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
    Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
    Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    J Cell Biochem; 2006 Apr; 97(5):1036-51. PubMed ID: 16294321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
    Regunathan J; Chen Y; Wang D; Malarkannan S
    Blood; 2005 Jan; 105(1):233-40. PubMed ID: 15328154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models.
    Konagai A; Yoshimura K; Hazama S; Yamamoto N; Aoki K; Ueno T; Fujioka M; Iijima H; Kato M; Uchida M; Wada T; Inoue M; Asao T; Fuse M; Wada S; Kuramasu A; Kamei R; Takeda S; Yamamoto S; Yoshino S; Oka M; Nagano H
    Anticancer Res; 2017 Aug; 37(8):4093-4101. PubMed ID: 28739693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions.
    Lodoen MB; Abenes G; Umamoto S; Houchins JP; Liu F; Lanier LL
    J Exp Med; 2004 Oct; 200(8):1075-81. PubMed ID: 15477345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
    Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
    Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
    Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
    Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
    Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK
    Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
    O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
    Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human tumor-derived exosomes down-modulate NKG2D expression.
    Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
    J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A possible mechanism of impaired NK cytotoxicity in cancer patients: down-regulation of DAP10 by TGF-beta1.
    Lee JC; Lee KM; Ahn YO; Suh B; Heo DS
    Tumori; 2011; 97(3):350-7. PubMed ID: 21789015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.